Novacept Sellers Benefited By Running IPO, M&A Processes Simultaneously
This article was originally published in The Gray Sheet
Executive Summary
Novacept cultivated interest among potential acquirers and added value to its eventual $325 mil. selling price by pursuing an IPO while at the same time moving down the merger & acquisition path, according to Piper Jaffray's Jeff Hoffman